Close

F8

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

This gene encodes coagulation factor VIII, which participates in the intrinsic pathway of blood coagulation; factor VIII is a cofactor for factor IXa which, in the presence of Ca+2 and phospholipids, converts factor X to the activated form Xa. This gene produces two alternatively spliced transcripts. Transcript variant 1 encodes a large glycoprotein, isoform a, which circulates in plasma and associates with von Willebrand factor in a noncovalent complex. This protein undergoes multiple cleavage events. Transcript variant 2 encodes a putative small protein, isoform b, which consists primarily of the phospholipid binding domain of factor VIIIc. This binding domain is essential for coagulant activity. Defects in this gene results in hemophilia A, a common recessive X-linked coagulation disorder. [provided by RefSeq, Jul 2008]
  • CAR Vector Products

Loading...
  • Target Species:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
XS-1222-ZP73 F8 (LDLR Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human F8-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP602 F8 (LRP1 Receptor) h(CD28-CD3ζ) Ligand-based CAR, pCDCAR1 Human F8-CD28-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP1473 F8 (LDLR Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human F8-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
XS-1222-ZP2002 F8 (LRP1 Receptor) h(41BB-CD3ζ) Ligand-based CAR, pCDCAR1 Human F8-41BB-CD6ζ Lentiviral vector T cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.